VitaSpring Biomedical Co., Ltd. (VSBC) reported no revenue for the three and six months ended July 31, 2026 and remains pre‑revenue while it rebuilds product offerings and sales channels in stem‑cell and exosome-based wellness and regenerative medicine markets. The company recorded a net loss of $155,817 for the quarter and $231,661 for the six months, compared with losses of $110,845 and $191,386 a year earlier, driven mainly by higher professional fees associated with public company reporting.
Liquidity is strained: cash was $13,367, current assets $14,822, current liabilities $2,266,051 and working capital deficit $2,251,229 as of July 31, 2026. Total liabilities were $4,677,051 and stockholders’ deficit $4,662,229, with an accumulated deficit of $5,928,532. A key vendor-related party agreed on May 18, 2026 to defer collection of $2,411,000 of payables for 24 months, which was reclassified to long‑term debt and accounted for as a Troubled Debt Restructuring with a 0% effective interest rate. The company discloses substantial doubt about its ability to continue as a going concern and continues to depend on unsecured, on‑demand advances from a former CEO and other related parties. Internal control over financial reporting has a continuing material weakness, and management changed in September 2026 with new leadership appointed and the prior CEO and director resigning.
VitaSpring Biomedical Co., Ltd. (VSBC) filed a late-filing notice for its Quarterly Report on Form 10-Q for the period ended July 31, 2026, citing a recent management and board transition, limited accounting personnel, and an existing material weakness in internal control over financial reporting. The company expects to file the Form 10-Q within the five-calendar-day extension period.
Preliminary results indicate a net loss of approximately $155,817 for the quarter, compared with $110,845 a year earlier, and a six‑month net loss of about $231,661 versus $191,386, driven mainly by higher professional fees. VitaSpring reports no revenue for either current or prior-year periods, as commercial sales have been suspended since the fiscal year ended January 31, 2022.
VITASPRING BIOMEDICAL CO., LTD. (VSBC) reports a leadership transition effective late on September 7, 2026. At 11:58 p.m. Pacific Time, Dr. Ssu‑Chuan Lai resigned as Chairperson of the Board, Chief Executive Officer, President, Chief Financial Officer, Secretary, and as a director. The company states that Dr. Lai’s resignation was not the result of any disagreement relating to operations, policies, or practices, and her resignation letter is included as an exhibit.
Immediately before this, Dr. Lai, as the sole director, elected Shao‑Hsiang Shih as a director at 11:56 p.m. and designated him Chairman at 11:57 p.m., and appointed Jing‑Zhou Chen as Chief Executive Officer, President, Chief Financial Officer, and Secretary at 11:57 p.m. Mr. Chen is designated as principal executive, financial, and accounting officer. Both Mr. Chen and Mr. Shih currently receive no compensation for their roles unless later determined by the board, have no disclosed related-party transactions or family relationships with existing officers or directors, and are entitled to indemnification and advancement of expenses to the fullest extent permitted by Nevada law and the company’s governing documents.
VitaSpring Biomedical Co., Ltd. reported no revenue for the three and six months ended July 31, 2025, as it remains a development-stage company focused on cell-based regenerative medicine concepts. The company recorded a net loss of $110,845 for the quarter and $191,386 for the six-month period, narrower than the prior-year losses due mainly to the elimination of lease and stock-based compensation costs.
Liquidity is extremely strained: cash was only $799, against current liabilities of $4,223,606, creating a working capital deficit of $4,215,713 and a stockholders’ deficit of $4,206,586. Related-party obligations are significant, including $2,411,000 of accounts payable to a related-party vendor and $917,020 of advances from a former CEO and other related parties. Management and the notes state that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and that continued operations depend on securing additional financing and ongoing related-party support.
The company currently has no active commercial operations, no R&D spending, and has not initiated clinical trials or obtained regulatory approvals. Internal control over financial reporting was deemed ineffective due to a material weakness tied to limited personnel and lack of SEC-reporting expertise, with remediation plans dependent on future funding. As of June 17, 2026, there were 207,030,030 common shares issued and outstanding.